Patents by Inventor Lily Wang

Lily Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180082473
    Abstract: Embodiments are directed to visualizing electromagnetic (EM) particle emissions in a computer-generated virtual environment. In one scenario, a computer system accesses portions of data representing EM particle emissions emitted by a virtualized EM particle emitter. The computer system generates a particle visualization that includes at least a portion of the EM particle emissions being emitted from the virtualized EM particle emitter within the virtual environment. The particle visualization includes an indication of the EM particle emissions' interactions with other virtual or non-virtual elements in the virtual environment. The computer system then presents the generated particle visualization in the computer-generated virtual environment. In some cases, the computer system further receives user input intended to interact with virtual elements within the virtual environment.
    Type: Application
    Filed: September 16, 2016
    Publication date: March 22, 2018
    Inventors: Nathan H. Stoddart, Adrian Musters, Thomas R. Giallorenzi, Zachary D. Jenkins, Joseph J. Booker, Braden J. Bartlett, David R. Heath, Ashley M. HOLT, Michael D. Jackson, Jason C. Newbold, Dallin S. Pabst, Jonathan C. Sanderson, Benjamin I. Smart, Lily Wang
  • Patent number: 9914711
    Abstract: The invention relates to a compound of formula I, and a preparation method and use thereof. The compound has a bacterial quorum-sensing regulatory effect, and can be used for prevention and/or treatment of a disease caused by a bacterial infection.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: March 13, 2018
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Junhai Xiao, Mingming Zhao, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xingzhou Li, Guoming Zhao, Xinbo Zhou, Xiaokui Wang, Wei Chen
  • Publication number: 20180053664
    Abstract: The embodiments of the present disclosure provide a bonding device for a chip on film and a display panel and a bonding method for the same. The bonding device includes: a bearing stage having a horizontal bearing surface for supporting at least one row of display panels, wherein one row of the at least one row of display panels has a row of first bonding regions; a grasping unit disposed above the bearing stage and configured to grasp at least a partial area of the entire chip on film so that a row of second bonding regions of the entire chip on film is horizontally located above the one row of display panels; and a bonding unit configured to bond the row of second bonding regions which has been aligned with the row of first bonding regions to the row of first bonding regions.
    Type: Application
    Filed: July 12, 2017
    Publication date: February 22, 2018
    Inventors: Lili Wang, Lu Wang
  • Patent number: 9890365
    Abstract: Non-viral delivery systems comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis and/or cirrhosis in OTCD patients by administering hOTC.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: February 13, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Lili Wang, James M. Wilson
  • Publication number: 20170362261
    Abstract: The invention relates to tizoxanide phosphate or alkane sulfonate compounds represented by Formula I, and pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof or solvates thereof, and pharmaceutical applications of the compounds.
    Type: Application
    Filed: December 11, 2015
    Publication date: December 21, 2017
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song LI, Xingzhou LI, Wu ZHONG, Zhibing ZHENG, Junhai XIAO, Xinbo ZHOU, Yunde XIE, Xiaokui WANG, Lili WANG, Wei CHEN, Fei XIE
  • Publication number: 20170334990
    Abstract: The present invention relates to a novel regulatory T cell protein. This protein, designated PD-L3 OR VISTA resembles members of the PD-L1 family, identified a novel and structurally-distinct, Ig-superfamily inhibitory ligand, whose extra-cellular domain bears homology to the B7 family ligand PD-L1. This molecule is designated as PD-L3 OR VISTA or V-domain Immunoglobulin Suppressor of T cell Activation (VISTA). Expression of VISTA is primarily within the hematopoietic compartment and is highly regulated on myeloid APCs and T cells. Therapeutic intervention of the VISTA inhibitory pathway represents a novel approach to modulate T cell-mediated immunity for the treatment of a wide variety of cancers, e.g., ovarian, bladder cancer and melanomas. Also, VISTA proteins, especially multimeric VISTA proteins and antibodies may be used to suppress T cell immunity in autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis and artritic conditions such as RA.
    Type: Application
    Filed: March 23, 2017
    Publication date: November 23, 2017
    Inventors: Randolph J. NOELLE, Lili WANG
  • Publication number: 20170330693
    Abstract: A photovoltaic device is provided. The photovoltaic device includes a metal salt layer disposed adjacent to a perovskite layer. The metal salt layer diffuses into the perovskite layer. Methods for fabricating the photovoltaic device are also provided.
    Type: Application
    Filed: May 11, 2017
    Publication date: November 16, 2017
    Applicant: Board of Trustees of Michigan State University
    Inventors: Richard R. LUNT, III, Lili WANG
  • Patent number: 9794362
    Abstract: Disclosed is a portal push method, which comprises: a broadband remote access server (BRAS) equipment acquiring a website identification list, after the BRAS equipment receives a hypertext transport protocol (HTTP) request message sent by a user terminal. The BRAS equipment determines whether to send portal pages to the user terminal according to whether the identification of a target website visited by the user client has a matched item in the list. The embodiments of the present disclosure further provide a corresponding BRAS equipment. The technical solutions of the embodiments of the present disclosure can reduce push times of invalid portals and improve portal push success rate.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: October 17, 2017
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Junli Hu, Lili Wang, Chi Zhang
  • Publication number: 20170190656
    Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a substituted acethydrazide derivative, preparation method and use thereof; preferably, relates to a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof can effectively inhibit proline hydroxylase, stabilize HIF-?, particularly HIF-1?, and has potency in the manufacture of a medicament for treatment and/or prophylaxis and/or adjuvant therapy of anemia, acute ischemic reperfusion injury.
    Type: Application
    Filed: May 20, 2015
    Publication date: July 6, 2017
    Applicant: Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. China
    Inventors: Song LI, Junhai XIAO, Lili WANG, Long LONG, Wei LI, Haoming LUO, Feifei LI, Wu ZHONG, Zhibing ZHENG, Yunde XIE, Xingzhou LI, Xinbo ZHOU, Xiaokui WANG, Ruiyuan CAO
  • Patent number: 9683988
    Abstract: The present invention provides a cell model and a method for screening c-Fms tyrosine kinase inhibitors. Specifically, the present invention provides a cell that expresses macrophage colony stimulating factor receptor and STAT1 protein simultaneously. The present invention further provides a method for screening c-Fms tyrosine kinase inhibitors, a method for evaluating the inhibiting activity of a compound or a composition against c-Fms tyrosine kinase, and use of the cell in screening c-Fms tyrosine kinase inhibitors. The cell model established in the present invention is sensitive, highly effective and reliable, and can be used in high-throughput screening and/or high-content screening of c-Fms tyrosine kinase inhibitors.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: June 20, 2017
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Lili Wang, Shengqian Yang, Long Long, Junhai Xiao, Song Li
  • Patent number: 9647928
    Abstract: A network device identifies an Open Shortest Path First (OSPF) link between the network device and a layer 2 network as one of a point-to-multipoint over broadcast interface or a point-to-multipoint over non-broadcast multi access (NBMA) interface, and performs database synchronization and neighbor discovery and maintenance using one of a broadcast model or a NBMA model. The network device also generates a link-state advertisement for the network device, where the link-state advertisement includes a separate link description for each point-to-point link within the layer 2 network; and sends the link-state advertisement to each fully adjacent neighbor in the layer 2 network.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: May 9, 2017
    Assignee: Juniper Networks, Inc.
    Inventors: Nischal Sheth, Zhaohui Zhang, Lili Wang
  • Patent number: 9630939
    Abstract: A derivative of homoserine lactone represented by formula I, and a preparation method and use thereof. The compound has a bacterial quorum-sensing regulatory effect, and can be used for prevention and/or treatment of a disease caused by a bacterial infection.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: April 25, 2017
    Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA
    Inventors: Song Li, Junhai Xiao, Mingming Zhao, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xingzhou Li, Guoming Zhao, Xinbo Zhou, Xiaokui Wang, Wei Chen
  • Patent number: 9631018
    Abstract: The present invention relates to a novel regulatory T cell protein. This protein, designated PD-L3 OR VISTA resembles members of the PD-L1 family, identified a novel and structurally-distinct, Ig-superfamily inhibitory ligand, whose extracellular domain bears homology to the B7 family ligand PD-L1. This molecule is designated as PD-L3 OR VISTA or V-domain Immunoglobulin Suppressor of T cell Activation (VISTA). Expression of VISTA is primarily within the hematopoietic compartment and is highly regulated on myeloid APCs and T cells. Therapeutic intervention of the VISTA inhibitory pathway represents a novel approach to modulate T cell-mediated immunity for the treatment of a wide variety of cancers, e.g., ovarian, bladder cancer and melanomas. Also, VISTA proteins, especially multimeric VISTA proteins and antibodies may be used to suppress T cell immunity in autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis and arthritic conditions such as RA.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: April 25, 2017
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Randolph J. Noelle, Lili Wang
  • Patent number: 9630957
    Abstract: Provided are a compound of formula I which can be used as a drug against small RNA virus infections, and optical isomers, pharmaceutically acceptable salts, solvates or hydrates thereof. Also provided are the preparation method of the compound, the method for using the compound for treating bacterial infections and the use of the compound in the preparation of a drug for preventing and/or treating viral diseases caused by small RNA viruses.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: April 25, 2017
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Junhai Xiao, Xian Zhang, Wu Zhong, Zhibing Zheng, Lili Wang, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang
  • Publication number: 20170051259
    Abstract: Viral vectors comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis cirrhosis in OTCD patients by administering hOTC.
    Type: Application
    Filed: March 9, 2015
    Publication date: February 23, 2017
    Inventors: Lili Wang, James M WILSON
  • Publication number: 20170037099
    Abstract: Disclosed are a low molecular polypeptide for preventing and treating inflammation, a preparation method and the use thereof and a pharmaceutical composition containing the polypeptide, wherein the polypeptide can penetrate the eye tissue barrier, can maintain a high concentration in neutral tears, aqueous humour and vitreous humour, and can be used to treat inflammation.
    Type: Application
    Filed: August 13, 2014
    Publication date: February 9, 2017
    Inventors: Xun XU, Lili WANG, Yi XU
  • Publication number: 20170021037
    Abstract: Non-viral delivery systems comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis and/or cirrhosis in OTCD patients by administering hOTC.
    Type: Application
    Filed: March 9, 2015
    Publication date: January 26, 2017
    Applicant: The Trustess of the University of Pennsylvania
    Inventors: Lili Wang, James M. Wilson
  • Publication number: 20170015874
    Abstract: Foamed pressure-sensitive adhesive tape having outstanding flame retardancy values and also very good technical adhesive properties comprising a foamed layer and an outer pressure sensitive adhesive layer wherein the outer pressure sensitive adhesive layer comprises at least 10 wt % of flame retardant and the foamed layer comprises less than 10 wt % of flame retardant or none, based in each case on the total weight of the layer in question.
    Type: Application
    Filed: July 12, 2016
    Publication date: January 19, 2017
    Applicant: TESA SE
    Inventors: Werner KLUGE-PALETTA, Karsten SEITZ, Weibin CHEN, Qin Lu, Lily Wang
  • Patent number: 9522891
    Abstract: Disclosed are pyridazine derivatives represented by Formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, methods of treating and/or preventing diseases or disorders associated with viral infections in patients using the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by Formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: December 20, 2016
    Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA
    Inventors: Song Li, Hongliang Wang, Junhai Xiao, Xian Zhang, Lili Wang, Zhibing Zheng, Wu Zhong, Yunde Xie, Xingzhou Li, Xinbo Zhou, Guoming Zhao, Xiaokui Wang
  • Patent number: 9518008
    Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: December 13, 2016
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., China
    Inventors: Song Li, Wu Zhong, Zhibing Zheng, Xinbo Zhou, Junhai Xiao, Yunde Xie, Lili Wang, Xingzhou Li, Guoming Zhao, Xiaokui Wang, Hongying Liu